Literature DB >> 27418622

Precision monitoring takes the stage.

Mark Roschewski1.   

Abstract

Year:  2016        PMID: 27418622      PMCID: PMC4946197          DOI: 10.1182/blood-2016-05-717520

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Next-Generation Sequencing in Oncology in the Era of Precision Medicine.

Authors:  Gideon M Blumenthal; Elizabeth Mansfield; Richard Pazdur
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Authors:  Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson
Journal:  Lancet Oncol       Date:  2015-04-01       Impact factor: 41.316

Review 3.  Novel targeted therapies in diffuse large B-cell lymphoma.

Authors:  Neha Mehta-Shah; Anas Younes
Journal:  Semin Hematol       Date:  2015-01-19       Impact factor: 3.851

Review 4.  Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Blood       Date:  2016-04-14       Impact factor: 22.113

5.  Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Authors:  Sarit E Assouline; Torsten Holm Nielsen; Stephen Yu; Miguel Alcaide; Lauren Chong; David MacDonald; Axel Tosikyan; Vishal Kukreti; Abbas Kezouh; Tina Petrogiannis-Haliotis; Marco Albuquerque; Daniel Fornika; Sepideh Alamouti; Remi Froment; Celia M T Greenwood; Kathleen Klein Oros; Errol Camglioglu; Ayushi Sharma; Rosa Christodoulopoulos; Caroline Rousseau; Nathalie Johnson; Michael Crump; Ryan D Morin; Koren K Mann
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

6.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

Review 7.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.